Cardioselective Antiischemic ATP-Sensitive Potassium Channel (KA TP) Openers. 6. Effect of Modifications at C6 of Benzopyranyl Cyanoguanidines

The effect on potency and selectivity of modifications at the C6 position of the cardioprotective KATP opener BMS-180448 (2) is described. Structure−activity studies show that a variety of electron-withdrawing groups (ketone, sulfone, sulfonamide, etc.) are tolerated for cardioprotective activity as...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of medicinal chemistry 1999-09, Vol.42 (18), p.3711-3717
Hauptverfasser: Ding, Charles Z, Rovnyak, George C, Misra, Raj N, Grover, Gary J, Miller, Arthur V, Ahmed, Syed Z, Kelly, Yolanda, Normandin, Diane E, Sleph, Paul G, Atwal, Karnail S
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3717
container_issue 18
container_start_page 3711
container_title Journal of medicinal chemistry
container_volume 42
creator Ding, Charles Z
Rovnyak, George C
Misra, Raj N
Grover, Gary J
Miller, Arthur V
Ahmed, Syed Z
Kelly, Yolanda
Normandin, Diane E
Sleph, Paul G
Atwal, Karnail S
description The effect on potency and selectivity of modifications at the C6 position of the cardioprotective KATP opener BMS-180448 (2) is described. Structure−activity studies show that a variety of electron-withdrawing groups (ketone, sulfone, sulfonamide, etc.) are tolerated for cardioprotective activity as measured by EC25 values for an increase in time to the onset of contracture in globally ischemic rat hearts. Changes made to the sulfonamido substituent indicate that compounds derived from secondary lipophilic amines are preferred for good cardioprotective potency and selectivity. The diisobutyl analogue 27 (EC25 = 0.04 μM) is the most potent compound of this series. The cardiac selectivity of 27 results from a combination of reduced vasorelaxant potency and enhanced cardioprotective potency relative to the potent vasodilating KATP openers (e.g., cromakalim). The diisobutylsulfonamide analogue 27 is over 4 orders of magnitude more cardiac selective than cromakalim (1). These results support the hypothesis that the cardioprotective and vasorelaxant properties of KATP openers follow distinct structure−activity relationships. The mechanism of action of 27 appears to involve opening of the cardiac KATP as its cardioprotective effects are abolished by the KATP blocker glyburide.
doi_str_mv 10.1021/jm990196h
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70032313</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70032313</sourcerecordid><originalsourceid>FETCH-LOGICAL-a444t-af796442ced87f316f63d87fb500b05a807ff9a0fa0e41cf58c5656450cf6e113</originalsourceid><addsrcrecordid>eNptkM-O0zAQhy0EYsvCgRdAPgBiDyn-F6c5dqNlQRS20gZxtFx3TF0Su9gJojwEz0xCqoUDpxnNfPpp5kPoKSVzShh9vW_LktBS7u6hGc0ZycSCiPtoRghjGZOMn6FHKe0JIZwy_hCdUSKKkhM2Q78qHbcuJGjAdO474KXvnEtmB60zeFmvs1vwyf1ZrUOnU3J9i6ud9h4a_Or9EtfrC3xzAA8xzbGc4ytrhygcLP4Qts46ozsXfMK6w5Ucx5fgf4bDMWp_bHB11D586bV3W-chPUYPrG4SPDnVc_TpzVVdvc1WN9fvquUq00KILtO2KKUQzMB2UVhOpZV87DY5IRuS6wUprC01sZqAoMbmC5PLXIqcGCuBUn6OXk65hxi-9ZA61Q5PQ9NoD6FPqhhUMU75AF5MoIkhpQhWHaJrdTwqStQoX93JH9hnp9B-08L2H3KyPQDPT4BORjd2UGBc-suVBcvZeFw2YS518ONureNXJQte5Kpe36qPoi5Wn68v1Rj7YuK1SWof-ugHdf-57zePq6cx</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70032313</pqid></control><display><type>article</type><title>Cardioselective Antiischemic ATP-Sensitive Potassium Channel (KA TP) Openers. 6. Effect of Modifications at C6 of Benzopyranyl Cyanoguanidines</title><source>MEDLINE</source><source>American Chemical Society Journals</source><creator>Ding, Charles Z ; Rovnyak, George C ; Misra, Raj N ; Grover, Gary J ; Miller, Arthur V ; Ahmed, Syed Z ; Kelly, Yolanda ; Normandin, Diane E ; Sleph, Paul G ; Atwal, Karnail S</creator><creatorcontrib>Ding, Charles Z ; Rovnyak, George C ; Misra, Raj N ; Grover, Gary J ; Miller, Arthur V ; Ahmed, Syed Z ; Kelly, Yolanda ; Normandin, Diane E ; Sleph, Paul G ; Atwal, Karnail S</creatorcontrib><description>The effect on potency and selectivity of modifications at the C6 position of the cardioprotective KATP opener BMS-180448 (2) is described. Structure−activity studies show that a variety of electron-withdrawing groups (ketone, sulfone, sulfonamide, etc.) are tolerated for cardioprotective activity as measured by EC25 values for an increase in time to the onset of contracture in globally ischemic rat hearts. Changes made to the sulfonamido substituent indicate that compounds derived from secondary lipophilic amines are preferred for good cardioprotective potency and selectivity. The diisobutyl analogue 27 (EC25 = 0.04 μM) is the most potent compound of this series. The cardiac selectivity of 27 results from a combination of reduced vasorelaxant potency and enhanced cardioprotective potency relative to the potent vasodilating KATP openers (e.g., cromakalim). The diisobutylsulfonamide analogue 27 is over 4 orders of magnitude more cardiac selective than cromakalim (1). These results support the hypothesis that the cardioprotective and vasorelaxant properties of KATP openers follow distinct structure−activity relationships. The mechanism of action of 27 appears to involve opening of the cardiac KATP as its cardioprotective effects are abolished by the KATP blocker glyburide.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/jm990196h</identifier><identifier>PMID: 10479302</identifier><identifier>CODEN: JMCMAR</identifier><language>eng</language><publisher>Washington, DC: American Chemical Society</publisher><subject>Animals ; Benzopyrans - chemical synthesis ; Benzopyrans - chemistry ; Benzopyrans - pharmacology ; Biological and medical sciences ; Cardiotonic Agents - chemistry ; Cardiotonic Agents - pharmacology ; Cardiovascular system ; Glyburide - pharmacology ; Guanidines - chemical synthesis ; Guanidines - chemistry ; Guanidines - pharmacology ; Heart - drug effects ; Medical sciences ; Miscellaneous ; Muscle Contraction - drug effects ; Myocardial Ischemia - drug therapy ; Pharmacology. Drug treatments ; Potassium Channels - agonists ; Rats ; Vasodilation - drug effects ; Vasodilator Agents - chemistry ; Vasodilator Agents - pharmacology</subject><ispartof>Journal of medicinal chemistry, 1999-09, Vol.42 (18), p.3711-3717</ispartof><rights>Copyright © 1999 American Chemical Society</rights><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a444t-af796442ced87f316f63d87fb500b05a807ff9a0fa0e41cf58c5656450cf6e113</citedby><cites>FETCH-LOGICAL-a444t-af796442ced87f316f63d87fb500b05a807ff9a0fa0e41cf58c5656450cf6e113</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/jm990196h$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/jm990196h$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,780,784,2765,27076,27924,27925,56738,56788</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1972521$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10479302$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ding, Charles Z</creatorcontrib><creatorcontrib>Rovnyak, George C</creatorcontrib><creatorcontrib>Misra, Raj N</creatorcontrib><creatorcontrib>Grover, Gary J</creatorcontrib><creatorcontrib>Miller, Arthur V</creatorcontrib><creatorcontrib>Ahmed, Syed Z</creatorcontrib><creatorcontrib>Kelly, Yolanda</creatorcontrib><creatorcontrib>Normandin, Diane E</creatorcontrib><creatorcontrib>Sleph, Paul G</creatorcontrib><creatorcontrib>Atwal, Karnail S</creatorcontrib><title>Cardioselective Antiischemic ATP-Sensitive Potassium Channel (KA TP) Openers. 6. Effect of Modifications at C6 of Benzopyranyl Cyanoguanidines</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>The effect on potency and selectivity of modifications at the C6 position of the cardioprotective KATP opener BMS-180448 (2) is described. Structure−activity studies show that a variety of electron-withdrawing groups (ketone, sulfone, sulfonamide, etc.) are tolerated for cardioprotective activity as measured by EC25 values for an increase in time to the onset of contracture in globally ischemic rat hearts. Changes made to the sulfonamido substituent indicate that compounds derived from secondary lipophilic amines are preferred for good cardioprotective potency and selectivity. The diisobutyl analogue 27 (EC25 = 0.04 μM) is the most potent compound of this series. The cardiac selectivity of 27 results from a combination of reduced vasorelaxant potency and enhanced cardioprotective potency relative to the potent vasodilating KATP openers (e.g., cromakalim). The diisobutylsulfonamide analogue 27 is over 4 orders of magnitude more cardiac selective than cromakalim (1). These results support the hypothesis that the cardioprotective and vasorelaxant properties of KATP openers follow distinct structure−activity relationships. The mechanism of action of 27 appears to involve opening of the cardiac KATP as its cardioprotective effects are abolished by the KATP blocker glyburide.</description><subject>Animals</subject><subject>Benzopyrans - chemical synthesis</subject><subject>Benzopyrans - chemistry</subject><subject>Benzopyrans - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Cardiotonic Agents - chemistry</subject><subject>Cardiotonic Agents - pharmacology</subject><subject>Cardiovascular system</subject><subject>Glyburide - pharmacology</subject><subject>Guanidines - chemical synthesis</subject><subject>Guanidines - chemistry</subject><subject>Guanidines - pharmacology</subject><subject>Heart - drug effects</subject><subject>Medical sciences</subject><subject>Miscellaneous</subject><subject>Muscle Contraction - drug effects</subject><subject>Myocardial Ischemia - drug therapy</subject><subject>Pharmacology. Drug treatments</subject><subject>Potassium Channels - agonists</subject><subject>Rats</subject><subject>Vasodilation - drug effects</subject><subject>Vasodilator Agents - chemistry</subject><subject>Vasodilator Agents - pharmacology</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkM-O0zAQhy0EYsvCgRdAPgBiDyn-F6c5dqNlQRS20gZxtFx3TF0Su9gJojwEz0xCqoUDpxnNfPpp5kPoKSVzShh9vW_LktBS7u6hGc0ZycSCiPtoRghjGZOMn6FHKe0JIZwy_hCdUSKKkhM2Q78qHbcuJGjAdO474KXvnEtmB60zeFmvs1vwyf1ZrUOnU3J9i6ud9h4a_Or9EtfrC3xzAA8xzbGc4ytrhygcLP4Qts46ozsXfMK6w5Ucx5fgf4bDMWp_bHB11D586bV3W-chPUYPrG4SPDnVc_TpzVVdvc1WN9fvquUq00KILtO2KKUQzMB2UVhOpZV87DY5IRuS6wUprC01sZqAoMbmC5PLXIqcGCuBUn6OXk65hxi-9ZA61Q5PQ9NoD6FPqhhUMU75AF5MoIkhpQhWHaJrdTwqStQoX93JH9hnp9B-08L2H3KyPQDPT4BORjd2UGBc-suVBcvZeFw2YS518ONureNXJQte5Kpe36qPoi5Wn68v1Rj7YuK1SWof-ugHdf-57zePq6cx</recordid><startdate>19990909</startdate><enddate>19990909</enddate><creator>Ding, Charles Z</creator><creator>Rovnyak, George C</creator><creator>Misra, Raj N</creator><creator>Grover, Gary J</creator><creator>Miller, Arthur V</creator><creator>Ahmed, Syed Z</creator><creator>Kelly, Yolanda</creator><creator>Normandin, Diane E</creator><creator>Sleph, Paul G</creator><creator>Atwal, Karnail S</creator><general>American Chemical Society</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19990909</creationdate><title>Cardioselective Antiischemic ATP-Sensitive Potassium Channel (KA TP) Openers. 6. Effect of Modifications at C6 of Benzopyranyl Cyanoguanidines</title><author>Ding, Charles Z ; Rovnyak, George C ; Misra, Raj N ; Grover, Gary J ; Miller, Arthur V ; Ahmed, Syed Z ; Kelly, Yolanda ; Normandin, Diane E ; Sleph, Paul G ; Atwal, Karnail S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a444t-af796442ced87f316f63d87fb500b05a807ff9a0fa0e41cf58c5656450cf6e113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Animals</topic><topic>Benzopyrans - chemical synthesis</topic><topic>Benzopyrans - chemistry</topic><topic>Benzopyrans - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Cardiotonic Agents - chemistry</topic><topic>Cardiotonic Agents - pharmacology</topic><topic>Cardiovascular system</topic><topic>Glyburide - pharmacology</topic><topic>Guanidines - chemical synthesis</topic><topic>Guanidines - chemistry</topic><topic>Guanidines - pharmacology</topic><topic>Heart - drug effects</topic><topic>Medical sciences</topic><topic>Miscellaneous</topic><topic>Muscle Contraction - drug effects</topic><topic>Myocardial Ischemia - drug therapy</topic><topic>Pharmacology. Drug treatments</topic><topic>Potassium Channels - agonists</topic><topic>Rats</topic><topic>Vasodilation - drug effects</topic><topic>Vasodilator Agents - chemistry</topic><topic>Vasodilator Agents - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ding, Charles Z</creatorcontrib><creatorcontrib>Rovnyak, George C</creatorcontrib><creatorcontrib>Misra, Raj N</creatorcontrib><creatorcontrib>Grover, Gary J</creatorcontrib><creatorcontrib>Miller, Arthur V</creatorcontrib><creatorcontrib>Ahmed, Syed Z</creatorcontrib><creatorcontrib>Kelly, Yolanda</creatorcontrib><creatorcontrib>Normandin, Diane E</creatorcontrib><creatorcontrib>Sleph, Paul G</creatorcontrib><creatorcontrib>Atwal, Karnail S</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ding, Charles Z</au><au>Rovnyak, George C</au><au>Misra, Raj N</au><au>Grover, Gary J</au><au>Miller, Arthur V</au><au>Ahmed, Syed Z</au><au>Kelly, Yolanda</au><au>Normandin, Diane E</au><au>Sleph, Paul G</au><au>Atwal, Karnail S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cardioselective Antiischemic ATP-Sensitive Potassium Channel (KA TP) Openers. 6. Effect of Modifications at C6 of Benzopyranyl Cyanoguanidines</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>1999-09-09</date><risdate>1999</risdate><volume>42</volume><issue>18</issue><spage>3711</spage><epage>3717</epage><pages>3711-3717</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><coden>JMCMAR</coden><abstract>The effect on potency and selectivity of modifications at the C6 position of the cardioprotective KATP opener BMS-180448 (2) is described. Structure−activity studies show that a variety of electron-withdrawing groups (ketone, sulfone, sulfonamide, etc.) are tolerated for cardioprotective activity as measured by EC25 values for an increase in time to the onset of contracture in globally ischemic rat hearts. Changes made to the sulfonamido substituent indicate that compounds derived from secondary lipophilic amines are preferred for good cardioprotective potency and selectivity. The diisobutyl analogue 27 (EC25 = 0.04 μM) is the most potent compound of this series. The cardiac selectivity of 27 results from a combination of reduced vasorelaxant potency and enhanced cardioprotective potency relative to the potent vasodilating KATP openers (e.g., cromakalim). The diisobutylsulfonamide analogue 27 is over 4 orders of magnitude more cardiac selective than cromakalim (1). These results support the hypothesis that the cardioprotective and vasorelaxant properties of KATP openers follow distinct structure−activity relationships. The mechanism of action of 27 appears to involve opening of the cardiac KATP as its cardioprotective effects are abolished by the KATP blocker glyburide.</abstract><cop>Washington, DC</cop><pub>American Chemical Society</pub><pmid>10479302</pmid><doi>10.1021/jm990196h</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-2623
ispartof Journal of medicinal chemistry, 1999-09, Vol.42 (18), p.3711-3717
issn 0022-2623
1520-4804
language eng
recordid cdi_proquest_miscellaneous_70032313
source MEDLINE; American Chemical Society Journals
subjects Animals
Benzopyrans - chemical synthesis
Benzopyrans - chemistry
Benzopyrans - pharmacology
Biological and medical sciences
Cardiotonic Agents - chemistry
Cardiotonic Agents - pharmacology
Cardiovascular system
Glyburide - pharmacology
Guanidines - chemical synthesis
Guanidines - chemistry
Guanidines - pharmacology
Heart - drug effects
Medical sciences
Miscellaneous
Muscle Contraction - drug effects
Myocardial Ischemia - drug therapy
Pharmacology. Drug treatments
Potassium Channels - agonists
Rats
Vasodilation - drug effects
Vasodilator Agents - chemistry
Vasodilator Agents - pharmacology
title Cardioselective Antiischemic ATP-Sensitive Potassium Channel (KA TP) Openers. 6. Effect of Modifications at C6 of Benzopyranyl Cyanoguanidines
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T17%3A06%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cardioselective%20Antiischemic%20ATP-Sensitive%20Potassium%20Channel%20(KA%20TP)%20Openers.%206.%20Effect%20of%20Modifications%20at%20C6%20of%20Benzopyranyl%20Cyanoguanidines&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Ding,%20Charles%20Z&rft.date=1999-09-09&rft.volume=42&rft.issue=18&rft.spage=3711&rft.epage=3717&rft.pages=3711-3717&rft.issn=0022-2623&rft.eissn=1520-4804&rft.coden=JMCMAR&rft_id=info:doi/10.1021/jm990196h&rft_dat=%3Cproquest_cross%3E70032313%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70032313&rft_id=info:pmid/10479302&rfr_iscdi=true